Amit Singh
Director, Delivery Discovery Mote Therapeutics
I have nearly 20 years of experience working with nanoparticles in drug discovery and drug product development. My key focus areas have been on nanoparticle-based targeted formulation development in early discovery, PD and drug product development for delivery of small molecules and nucleic acids for a variety of therapeutic applications. I have previously worked on various inorganic, polymeric and lipid-based therapeutics and my current focus is on targeted delivery of LNPs to extra-hepatic tissues harnessing the potential of targeting ligands as well as routes of administration. I have previously worked as Head of Nonviral delivery for gene therapy at Takeda.
Seminars
Tuesday 7th April 2026
Panel Discussion: Reformulating LNPs to Achieve Extrahepatic Delivery & Expand Therapeutic Reach
2:30 pm
- Which extrahepatic targets remain the greatest unmet clinical need?
- What are the inherent biological challenges that are limiting LNPs from moving beyond the liver?
- How to better leverage formulation and administration routes to enable effective extrahepatic targeting?
Tuesday 7th April 2026
Engineering LNPs to Detarget the Liver by Balancing Circulation Time & Targetability for More Efficacious Drug Products
1:30 pm
- Exploring the application of non-sheddable PEGylation to prolong systemic circulation
- Addressing the challenge of prolonging circulation whilst still maintaining efficacy and potency
- Applying targeting strategies using surface-conjugated moieties to drive tissue-specific delivery
NEW DATA
